



**CE Marked Material**

**QCRHBsGQC2 - Anti-HBsAg Quality Control Serum Sample 2**

**NIBSC code: QCRHBsGQC2**

**Instructions for use**

**(Version 4.0, Dated 13/03/2024)**

This material is an 'Annex II List A' IVD and complies with the requirements of the "EU in vitro diagnostic medical device directive 98/79/EC"

**1. INTENDED USE**

**This product is CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.**

This product is (22/B893) CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.

HBsAg QC2 is intended for use in the internal laboratory quality control of immunoassays that detect hepatitis B surface antigen. The HBsAg QC2 should be included in each run as part of a continuing quality control programme to monitor the performance of the assay. Data obtained with the HBsAg QC2 can be used to construct quality control charts that can be visually monitored each time the assay is run, to check for consistency of performance of the assay. Examples of how these charts are constructed and used have been described elsewhere.

HBsAg QC2 is NOT INTENDED TO BE USED TO COMPARE THE SENSITIVITY OF PARTICULAR ASSAYS.

**2. CAUTION**

**The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. This preparation is not for administration to humans or animals**

**3. UNITAGE**

Table 1 gives a summary of the results obtained for Hepatitis B surface antigen QC2 22/B893. These results are intended only as a guide to the approximate levels of reactivity to be expected, and may not be exactly reproduced in other laboratories. In each case, at a minimum, three samples of Hepatitis B surface antigen QC2 were tested on two separate occasions. The results are expressed as the ratio of mean optical density or other measurement of the Hepatitis B surface antigen response of the QC2 sample, to the kit manufacturer's calculated cut-off.

**4. CONTENTS**

Country of origin of biological material: United Kingdom.

Country of origin of biological material: United Kingdom.

Ready-to-use reagent

REF QCRHBsGQC2 1x7mL Blood tube

Defibrinated Plasma 4mL

Bronidox® 0.05% (w/v)

**5. STORAGE**

- Reagents are to be kept at 2-8°C upon receipt
- Reagents may be stored at 2-8°C until use by date
- Reagents should be divided into measured sub-aliquots of one use and stored below -20°C to avoid freeze/thaw cycles.
- Reagents may be stored at -20°C until use by date.

- When thawed for use, store at 2-8°C. Once thawed, use within one month and do not refreeze.
  - Ensure all containers are properly sealed to avoid drying out of the reagent
  - Avoid microbial contamination of this product as this may alter product performance
  - Avoid excessively high temperatures or humidity
- Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

**6. DIRECTIONS FOR OPENING**

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

**7. USE OF MATERIAL**

1. Use of this reagent is to be restricted to trained laboratory staff only
2. Use suitable (latex/nitrile) gloves and eye/skin protection
3. Include reagent as a normal sample in routine work list
4. Allow reagent to reach room temperature before use
5. Plot reagent result to monitor performance

The Result Reporting System (RRS) has been developed by the National Institute for Biological Standards and Control (NIBSC) for the data monitoring of its serology and NAT quality control (QC) reagents. These include the Quality Control Reagent Unit (QCRU) and Clinical Virology Network (CVN) reagents. The system has been successfully running for serology assays for several years collecting thousands of data points a year. The system has recently been developed to accept data for Nucleic Acid-based Technologies (NAT) reagents and associated assays.

<https://www.nibsc.org/products/rrs.aspx>

**8. STABILITY**

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

**9. REFERENCES**

1. Levey, S. and Jennings, E.R. (1950) The use of control charts in clinical laboratories. *Am.J.Clin.Pathol.* 20, 1059-1066

**10. ACKNOWLEDGEMENTS**

EC REP Advena Ltd. Tower Business Centre, 2nd Floor, Swatar, BKR 4013, Malta

**11. FURTHER INFORMATION**

Further information can be obtained as follows;

This material: [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

WHO Biological Standards:

<http://www.who.int/biologicals/en/>

JCTLM Higher order reference materials:

<http://www.bipm.org/en/committees/jc/jctlm/>

Derivation of International Units:



[http://www.nibsc.org/standardisation/international\\_standards.aspx](http://www.nibsc.org/standardisation/international_standards.aspx)

Ordering standards from NIBSC:

<http://www.nibsc.org/products/ordering.aspx>

NIBSC Terms & Conditions:

[http://www.nibsc.org/terms\\_and\\_conditions.aspx](http://www.nibsc.org/terms_and_conditions.aspx)

## 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

## 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

## 14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify): Contains Bronidox	
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	

## 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About\\_Us/Terms\\_and\\_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this

document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

## 16. INFORMATION FOR CUSTOMS USE ONLY

<b>Country of origin for customs purposes*:</b> United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
<b>Net weight:</b> 4g
<b>Toxicity Statement:</b> Toxicity not assessed
<b>Veterinary certificate or other statement</b> if applicable.
<b>Attached:</b> No





**Table 1**

Results obtained for HBsAg QC2 (Lot Number 22/B893) using the following EIA kits.

Assay	Method Option	Test to Cut-Off Ratio	
		Mean	SD (n-1)
<b>Liaison XL Murex HBsAg Quant</b> Manufacturer: DiaSorin Catalogue Number: 310250 Kit Lot: 132057, 132058	Automated	0.21 (IU/mL)	0.02
<b>Murex HBsAg Version 3</b> Manufacturer: DiaSorin Catalogue Number: 9F80-01 Kit Lot: D918410, D923810	Standard Protocol	2.528 (OD/CO)	0.24